Acute myeloid leukemia
Conditions
Interventions
trial group:Low-dose venetoclax group (venetoclax 100-200mg/d, d1-28), combined with azole antifungal drugs (voriconazole, posaconazole, itraconazole, esaconazole and fluconazole, etc.)
Control group:The other group was full dose venetoclax (full dose group, not combined with azole antifungal drugs 100mg/d on the first day, 200mg/d on the second day, 400mg/d on the third day and ther
Sponsors
The First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: Treatment-naive patients with AML who could not tolerate intensive chemotherapy were eligible for the protocol. 1. Definitive diagnosis of AML by MICM typing (excluding acute promyelocytic leukemia Disease M3); 2 over 14 years of age, regardless of gender or race; 3. Physical status: ECOG score 0-3; 4. Cardiac function: left ventricular ejection fraction = 40%; 5. Expected survival time > 12 weeks; 6. Serum creatinine (Cr) =1.5×ULN (upper limit of normal), alanine aminotransferase (ALT) Aspartate aminotransferase (AST) =2.5×ULN, total bilirubin =1.5×ULN; 7. The patient is self-aware and able to sign informed consent; The guardian of the child patient provided consent Informed consent was obtained.
Exclusion criteria
Exclusion criteria: 1. Except for secondary AML; 2. pregnant or lactating women; 3. active HBV or HCV infection; 4. People living with HIV;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse effects; | — |
Countries
China
Contacts
Public ContactJuan Tong
The First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)
Outcome results
None listed